SUTRO BIOPHARMA INC. - COMMON STOCK

Sutro Biopharma to Highlight its Next-Generation Exatecan and Dual-Payload ADC Programs in Presentations at AACR 2025

28 أبريل 2025 16:05:00 بحسب Nasdaq GlobeNewswire

Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

15 مارس 2025 18:40:00 بحسب Nasdaq GlobeNewswire

Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights

13 مارس 2025 16:07:00 بحسب Nasdaq GlobeNewswire

Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline

13 مارس 2025 16:05:00 بحسب Nasdaq GlobeNewswire

Sutro Biopharma to Present at the TD Cowen 45th Annual Health Care Conference

03 مارس 2025 16:05:00 بحسب Nasdaq GlobeNewswire

Sutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference 

07 يناير 2025 16:05:03 بحسب Nasdaq GlobeNewswire

Sutro Biopharma and Boehringer Ingelheim BioXcellence™ collaboration: Established first-in-class cell-free capabilities at commercial scale

07 يناير 2025 09:00:00 بحسب Nasdaq GlobeNewswire

Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results from Dose-Optimization Portion of REFRαME-O1 Trial in Platinum Resistant Ovarian Cancer

10 ديسمبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights

13 نوفمبر 2024 16:30:00 بحسب Nasdaq GlobeNewswire

Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference

04 نوفمبر 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML

01 نوفمبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum

10 أكتوبر 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

20 سبتمبر 2024 16:01:00 بحسب Nasdaq GlobeNewswire

Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024

14 سبتمبر 2024 03:00:00 بحسب Nasdaq GlobeNewswire

Sutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10, 2024

11 سبتمبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Sutro Biopharma Announces Initiation of REFRαME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer

22 أغسطس 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Sutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones

13 أغسطس 2024 16:30:00 بحسب Nasdaq GlobeNewswire

Sutro Biopharma Appoints Dr. Barbara Leyman as Chief Business Development Officer

09 يوليو 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones

13 مايو 2024 16:30:00 بحسب Nasdaq GlobeNewswire

Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 Trial

30 أبريل 2024 08:00:01 بحسب Nasdaq GlobeNewswire